Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma
Metrics: PDF 2086 views | HTML 2136 views | ?
Longmei Cai1,*, Jinbang Li1,*, Xiaona Zhang1,4,*, Yaoyong Lu1,5,*, Jianguo Wang1, Xiaoming Lyu1,3, Yuxiang Chen1, Jinkun Liu2, Hongbing Cai2, Ying Wang1, Xin Li1
1Cancer Research Institute, Southern Medical University, Guangzhou 510515, China
2School of Chinese Traditional Medicine, Southern Medical University, Guangzhou 510515, China
3Central Medical Laboratory, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510515, China
4The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China
5Department of Radiation Oncology, Gaozhou People's Hospital, Gaozhou 525200, China
* These authors contributed equally.
Xin Li, e-mail: email@example.com
Ying Wang, e-mail: firstname.lastname@example.org
Hongbing Cai, e-mail: email@example.com
Keywords: Nasopharyngeal carcinoma, EBV-miR-BART7, tumorigenesis, therapeutic experiment
Received: September 15, 2014 Accepted: January 07, 2015 Published: February 19, 2015
Epstein-Barr virus (EBV) infection is a major etiological factor for nasopharyngeal carcinoma (NPC). Several EBV-encoded BART miRNAs have been associated with viral latency, immune escape, cell survival, cell proliferation and apoptosis. Here, we report that EBV-miR-BART7-3p, an EBV-encoded BART miRNA highly expressed in NPC, was correlated with cell-cycle progression in vitro and increased tumor formation in vivo. This viral miRNA stimulated the PTEN/PI3K/Akt pathway and induced c-Myc and c-Jun. Knockdown of PTEN mimicked EBV-miR-BART7-3p-induced tumorigenic phenotype. Based on these results, we conducted a therapeutic experiment by using gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p. Silencing of EBV-miR-BART7-3p reduced tumor growth in animal model. We conclude that EBV-miR-BART7-3p favors carcinogenesis, representing a potential target for miRNA-based therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.